{"id":7461,"date":"2021-02-04T15:08:29","date_gmt":"2021-02-04T14:08:29","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=7461"},"modified":"2021-10-11T15:55:37","modified_gmt":"2021-10-11T14:55:37","slug":"webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/","title":{"rendered":"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021"},"content":{"rendered":"\n<p><a href=\"https:\/\/gardp.org\/news-resources\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate\/\" target=\"_blank\" rel=\"noreferrer noopener\">Live webinar<\/a> organized by the &nbsp;Global Antibiotic Research and Development Partnership, <a href=\"https:\/\/gardp.org\/who-we-are\/about-gardp\/\" target=\"_blank\" rel=\"noreferrer noopener\">GARDP<\/a>, that will be broadcast on 25 February 2021 at 17:00-18:30 CET. Find your time zone&nbsp;<a href=\"https:\/\/www.timeanddate.com\/worldclock\/converter.html?iso=20210225T160000&amp;p1=87\">here<\/a>.<\/p>\n\n\n\n<p><strong>Speakers:<\/strong><\/p>\n\n\n\n<ul><li>Patricia Bradford, Antimicrobial Development Specialists LLC (US)<\/li><li>Alita Miller, Entasis Therapeutics (US)<\/li><\/ul>\n\n\n\n<p><strong>Moderator:<\/strong>&nbsp;Michael Mourez, \u00c9cole d\u2019Ing\u00e9nieurs de PURPAN (France)<\/p>\n\n\n\n<p>Presentations:<\/p>\n\n\n\n<p>Screen to pre-clinical candidate (Alita Miller):<\/p>\n\n\n\n<ul><li>Discovery strategies<\/li><li>Hit-to-lead generation<\/li><li>MOA studies<\/li><li>Spectrum of activity<\/li><li>Resistance studies<\/li><li>In vitro toxicity assessments<\/li><li>PK\/PD characterization<\/li><\/ul>\n\n\n\n<p>Pre-clinical candidate to phase 1 (Patricia Bradford):<\/p>\n\n\n\n<ul><li>Non-clinical package requirements for first-in-human studies<\/li><li>Dose selection<\/li><li>Non-clinical toxicity<\/li><li>CMC considerations<\/li><li>Regulatory process\/pathways<\/li><\/ul>\n\n\n\n<p>The presentations will be followed by a Q&amp;A session.<\/p>\n\n\n\n<p>If you have questions or comments, please let us know:&nbsp;<a href=\"mailto:revive@gardp.org\">revive@gardp.org<\/a>.<\/p>\n\n\n\n<p>Registration <a href=\"https:\/\/register.gotowebinar.com\/register\/8974462807057685772?source=GARDP\" target=\"_blank\" rel=\"noreferrer noopener\">on the Global Antibiotic Research and Development website<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Live webinar organized by the &nbsp;Global Antibiotic Research and Development Partnership, GARDP, that will be broadcast on 25 February 2021 at 17:00-18:30 CET. Find your time zone&nbsp;here. Speakers: Patricia Bradford, Antimicrobial Development Specialists LLC (US) Alita Miller, Entasis Therapeutics (US) Moderator:&nbsp;Michael Mourez, \u00c9cole d\u2019Ing\u00e9nieurs de PURPAN (France) Presentations: Screen to pre-clinical candidate (Alita Miller): Discovery [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":7463,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[35],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021 - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021 - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-04T14:08:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-11T14:55:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"927\" \/>\n\t<meta property=\"og:image:height\" content=\"267\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021\",\"datePublished\":\"2021-02-04T14:08:29+00:00\",\"dateModified\":\"2021-10-11T14:55:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/\"},\"wordCount\":141,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg\",\"articleSection\":[\"Ev\u00e8nements &amp; Colloques\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/\",\"name\":\"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021 - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg\",\"datePublished\":\"2021-02-04T14:08:29+00:00\",\"dateModified\":\"2021-10-11T14:55:37+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg\",\"width\":927,\"height\":267,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ev\u00e8nements &amp; Colloques\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021 - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/","og_locale":"fr_FR","og_type":"article","og_title":"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021 - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2021-02-04T14:08:29+00:00","article_modified_time":"2021-10-11T14:55:37+00:00","og_image":[{"width":927,"height":267,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021","datePublished":"2021-02-04T14:08:29+00:00","dateModified":"2021-10-11T14:55:37+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/"},"wordCount":141,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg","articleSection":["Ev\u00e8nements &amp; Colloques"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/","name":"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021 - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg","datePublished":"2021-02-04T14:08:29+00:00","dateModified":"2021-10-11T14:55:37+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/02\/Webinar-icon.jpg","width":927,"height":267,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/webinar-from-discovery-to-the-pre-clinical-antimicrobial-candidate-25-february-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Ev\u00e8nements &amp; Colloques","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/evenements-colloques\/"},{"@type":"ListItem","position":4,"name":"Webinar: From discovery to the pre-clinical antimicrobial candidate, 25 February 2021"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-12 23:25:57","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/7461"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=7461"}],"version-history":[{"count":10,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/7461\/revisions"}],"predecessor-version":[{"id":17991,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/7461\/revisions\/17991"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/7463"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=7461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=7461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=7461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}